- Market Capitalization, $K 13,247,241
- Shares Outstanding, K 111,490
- Annual Sales, $ 74,910 K
- Annual Income, $ -761,500 K
- 60-Month Beta 2.44
- Price/Sales 74.89
- Price/Cash Flow N/A
- Price/Book 8.28
|Period||Period Low||Period High||Performance|
| || |
+2.27 (+1.95%)since 12/17/19
| || |
+36.94 (+45.11%)since 10/17/19
| || |
+38.14 (+47.27%)since 01/17/19
USA News Group - A new study out suggests that T cells are a subset of lymphocytes (white blood cells), which play a key role in the body's immune response. This new information could prove to be a key...
Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $112.48 to a high of $118.49. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of...
Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.
--- As of Year-End 2019, Over 750 Patients Worldwide Receiving Commercial ONPATTRO and Over 1,000 Total Patients Worldwide Being Treated with Patisiran -
--- Lumasiran Granted Pediatric Rare Disease Designation by FDA for the Treatment of PH1 -
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference...
Shares of Alnylam (ALNY) rise on significant pipeline progress.
Smart Beta ETF report for EUSA
Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.
--a^' Alnylam Intends to File New Drug Application (NDA) and Marketing Authorisation Application (MAA) in Early 2020 -